Gene-sequencing giant Illumina is laying off 96 employees from its San Diego headquarters, according to paperwork filed with the state. This workforce reduction comes at a time when Illumina is ...

The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country.

11 analysts have expressed a variety of opinions on Illumina ILMN over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...

In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

Here are the biggest headlines of the day in the latest Market Minute. Illumina (ILMN) shares have recouped their losses. The stock had fallen after China banned it from exporting its gene ...

SHANGHAI - China announced a ban on March 4 on imports of genetic sequencers from US medical equipment maker Illumina, just minutes after US President Donald Trump’s additional 10 per cent ...

In its fourth quarter 2024 investor letter, Brown Advisors Global Leaders Strategy emphasized stocks such as Illumina, Inc. (NASDAQ:ILMN). Illumina, Inc. (NASDAQ:ILMN) offers sequencing- and array ...

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...

China’s Ministry of Commerce said it would ban Illumina, a San Diego company, from importing its gene-mapping products in China. Illumina is the world’s leading producer of gene-sequencing ...

China Bans Imports of Illumina's Gene Sequencers Right After Trump Tariff Action By Andrew Silver SHANGHAI (Reuters) -China announced a ban on Tuesday on imports of genetic sequencers from U.S ...

BEIJING’S surprise move to blacklist Illumina has unleashed a frenzy among the US firm’s Chinese rivals to win market share from the gene-sequencing giant. While Illumina is still assessing the ...